Nascent Biotech (NBIO) Action Cours

Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of monoclonal antibodies for the treatment of various forms of cancer. The company is headquartered in North Palm Beach, Florida. The company went IPO on 2012-06-06. The firm focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The company owns a drug candidate, Pritumumab, which the Company is developing as a treatment for epithelial cancers that includes lung, breast, colon, brain, and pancreas. Its initial focus is on patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma. The firm is exploring Pritumumab in its use against viruses. The firm is also engaged in developing a traditional vaccine platform to create vaccines for viral infections.